IRCT20211221053470N1 IRCT 2022-01-11 World Health Organization WHO Solidarity Plus An international randomised trial of additional treatments (Arttesunate, Infliximab, Imatinib) for COVID-19 in hospitalised patients who are all receiving the local standard of care 2022-01-21 anticipated 1000 Complete https://irct.ir/trial/60815 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The WHO Solidarity PLUS Trial in Iran will initially evaluate two treatment arms: infliximab and imatinib, in addition to the local standard of care. These drugs were chosen after careful consideration of potential drugs by an independent panel of experts. Based on available data, these drugs were selected for their potential to reduce mortality. Once electronic data collection has been completed the patient automatically enters the trial and a random allocation of their trial treatment is generated (by an algorithm that ensures eventual balance in the characteristics just recorded between each study drug and its controls) and displayed. The patients will be randomly allocated either to local Standard of Care alone or to local Standard of Care plus one of the study drugs: Group 1: local standard of care + Infliximab (5 mg/kg/dose (once only), single IV infusion over 2 hours) • Group 2: local standard of care + Imatinib (400 mg/dose; orally once daily; duration of treatment 14 days) • Group 3: local standard of care. 3 covid-19. Intervention 1: Intervention group 1: standard local treatment + infleximab (5mg / kg / dose only single dose as intravenous infusion given to the patient within 2 hours). Intervention 2: Intervention group 2: standard local treatment + imatinib (400 mg / dose orally once daily for 14 days). Intervention 3: Control group: standard local treatment according to national guideline. No - There is not a plan to make this available Justification or reason for not sharing IPD is This is a part of an international multi-center study with sponsorship of World Health Organization, and publishing of data should be authorized by WHO.